Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer ...

U.S. health officials are asking retailers to pull a small number of acne creams from their store shelves after government testing found they contain slightly elevated levels ...

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY ...

Basel, 5 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has ...

Explore why Recursion Pharmaceuticals' AI-driven drug discovery faces challenges in revenue growth, governance, and investor ...

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a complete renal response benefit1 The filing application is based on data from the phase ...

Study participants in GRADUATE 1 and 2 treated with gantenerumab showed a slowing of clinical decline of -0 ... Roche were down nearly 5% in the wake of the announcement, but its partner for the ...

Kohl's Corp forecast a bigger drop in annual comparable sales than expected on Tuesday, piling on more pressure on new boss ...